Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer

• Main Authors: Karl Brendel (Author), Tanios Bekaii‐Saab (Author), Patrick M Boland (Author), Farshid Dayyani (Author), Andrew Dean (Author), Teresa Macarulla (Author), Fiona Maxwell (Author), Kabir Mody (Author), Anna Pedret‐Dunn (Author), Zev A Wainberg (Author), Bin Zhang (Author)
• Format: Book
• Published: Wiley, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440). Adequacy of the model was assessed using multiple method...